FDA’s FY2025 report counted 1,309 drug-quality inspections, and regulators classified 18% as Official Action Indicated, meaning nearly one in five inspections identified serious compliance concerns. Therefore, as digitalization in pharma industry accelerates, inspectors increasingly review batch records, expiry controls, user access, audit trails, and system changes. C Square pharma software can support these activities through integrated ERP and distribution workflows; however, the platform alone cannot guarantee GMP compliance. Companies must also validate the system, control master data, review audit trails, and maintain reliable electronic records.
This article explains where C Square PharmAssist can help, where its compliance limits begin, and which records inspectors may request.
Table of Contents
What Is C Square Pharma Software?
C Square pharma software refers to a suite of business applications that supports pharmaceutical supply-chain operations. Its product range includes PharmAssist for distribution and inventory management, EcoGreen for pharmacy retail, StoreTrack for warehouse processes, LiveOrder for digital ordering, and SFA360 for sales-force management. Therefore, pharmaceutical companies, wholesalers, pharmacies, and warehouses can use these connected tools to manage purchases, batches, expiry dates, stock, orders, dispatches, billing, and field-sales activities.
However, companies should assess each application separately because features, integrations, and compliance controls may differ across the C Square product suite.
Why Pharma ERP Software Matters for GMP and GDP Compliance?
Pharma ERP software can connect batch, expiry, inventory, supplier, customer, and distribution records in one system. Therefore, it improves traceability and helps teams respond faster during GMP and GDP inspections.
However, software alone does not ensure compliance. Companies must validate the system, control access, review audit trails, maintain accurate data, train users, and follow approved procedures.
Four Pharma ERP Controls Inspectors Examine Closely
Inspectors do not assess an ERP system by its feature list alone. Instead, they examine whether the company uses its controls to protect traceability, data integrity, product quality, and business continuity throughout regulated operations. The following areas often reveal whether an organization maintains reliable and inspection-ready records:
- Batch Tracking and Expiry Control (PDF)
- Distribution Records and Recall Readiness (PDF)
- User Access, Audit Trails, and Data Integrity (PDF)
- Validation, Change Control, and Data Recovery (PDF)
Batch Tracking and Expiry Control (PDF)
PharmAssist can track batches, expiry dates, receipts, and stock movements. Therefore, inspectors may verify traceability and expired-stock controls.
Download the WHO Guide to Batch and Expiry Control Here
The following infographic shows how C Square PharmAssist can track pharmaceutical products from receipt and batch registration to storage, FEFO distribution, and expiry control.
Distribution Records and Recall Readiness (PDF)
The system can link delivered batches with customers, invoices, returns, and warehouse transactions. As a result, companies can identify affected products quickly and support an effective recall.
User Access, Audit Trails, and Data Integrity (PDF)
Companies should assign individual accounts and limit system access according to each user’s responsibilities. Inspectors may also review record changes, deletions, audit trails, and management oversight.
Validation, Change Control, and Data Recovery (PDF)
Companies should validate critical ERP functions and document configuration or software changes. In addition, they must test backups, data restoration, disaster recovery, and system continuity procedures.
Where C Square Implementations Create Compliance Risk
C Square pharma software can support controlled inventory and distribution, but poor implementation can create compliance gaps. Common risks include weak configuration, unclear procedures, excessive access, incomplete data migration, and unsupported vendor claims. The table below summarizes the main risks inspectors may examine.
| Implementation Riskstage | How the Gap Develops | Potential Inspection Finding | Required Control |
|---|---|---|---|
|
Unsuitable configuration |
Teams configure batch, expiry, approval, or warehouse rules without assessing GMP and GDP requirements. |
The system permits incorrect stock movements, expired-product handling, or uncontrolled transactions. |
Define user requirements, assess risks, and test every critical configuration. |
|
Weak procedures and training |
SOPs fail to explain data entry, exception handling, audit-trail review, and record correction. |
Users follow inconsistent workflows or create incomplete records. |
Create clear SOPs, train users, and verify routine compliance. |
|
Uncontrolled user access |
Administrators grant excessive permissions or allow shared accounts. |
Users can change, delete, or approve records without adequate accountability. |
Apply unique accounts, role-based access, periodic reviews, and controlled administrator rights. |
|
Poor data migration |
Teams transfer legacy records without checking completeness, accuracy, and context. |
Migrated batch, customer, inventory, or transaction data does not match the original records. |
Approve a migration plan, reconcile records, test results, and document exceptions. |
|
Unsupported compliance claims |
Companies assume that vendor statements such as “GMP compliant” replace validation evidence. |
The organization cannot show approved requirements, risk assessments, test records, or intended-use validation. |
Evaluate supplier claims and validate the configured system for its actual regulated use. |
What Evidence Should Be Ready for Inspection?
Inspectors expect documented evidence, not vendor brochures or screenshots. Companies should prepare validation records, access reviews, audit trails, batch and expiry reports, recall tests, backups, change controls, training files, and migration checks. Each record should link to an approved procedure, responsible user, and documented review.
The following C Square ERP inspection evidence map shows the key records, controls, and documents that pharmaceutical distributors should prepare for GMP and GDP inspections.
Final Words
FDA completed 1,248 drug-quality assurance inspections in FY2025, nearly 28% more than in FY2024. Therefore, pharmaceutical companies should expect inspectors to examine how digital systems control records, access, traceability, and routine decisions. C Square pharma software can support stronger distribution controls; however, companies must configure, validate, and monitor it according to its intended GMP and GDP use. Ultimately, inspection readiness depends on consistent evidence, not software claims alone.
Digital Solutions for GMP Operations
We support pharmaceutical teams in implementing, maintaining, and optimizing GMP software, data management systems, and computerized workflows that strengthen compliance, data integrity, and operational efficiency.
FAQ
No. GMP compliance depends on the configured system, validated intended use, approved procedures, controlled access, trained users, and routine quality oversight.
Companies should prepare validation evidence, access reviews, audit trails, batch and expiry reports, distribution records, recall tests, change controls, backup results, and training files.
Yes. The company should validate every function that creates, changes, stores, or reports data used in regulated inventory and distribution processes.
References
Reza Esmaeili is a technology and product leader in Germany, combining CTO and CPO experience to bridge engineering execution with customer-driven product strategy. He has led cloud and automation initiatives that improved operational efficiency and reduced costs. He has managed cross-functional teams of engineers and product managers and brought new software products from concept to market. He focuses on building data-driven product organizations by introducing analytics to track performance and guide decisions. He champions Agile ways of working to shorten feedback loops, improve quality, and accelerate go-to-market execution in close partnership with sales and marketing.